Trial Profile
Efficacy and safety of combination therapy of tocilizumab and abatacept in patients with refractory systemic-onset juvenile idiopathic arthritis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2016
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 30 Sep 2016 New trial record